Zynex Inc. (ZYXI): Price and Financial Metrics


Zynex Inc. (ZYXI): $15.22

-0.11 (-0.72%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ZYXI Stock Summary

  • Price to trailing twelve month operating cash flow for ZYXI is currently 653.11, higher than 99.09% of US stocks with positive operating cash flow.
  • Of note is the ratio of Zynex Inc's sales and general administrative expense to its total operating expenses; 87.4% of US stocks have a lower such ratio.
  • Revenue growth over the past 12 months for Zynex Inc comes in at 76.2%, a number that bests 93.41% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Zynex Inc are GDOT, FSS, INOD, SCHN, and SMED.
  • Visit ZYXI's SEC page to see the company's official filings. To visit the company's web site, go to www.zynex.com.

ZYXI Stock Price Chart Interactive Chart >

Price chart for ZYXI

ZYXI Price/Volume Stats

Current price $15.22 52-week high $29.73
Prev. close $15.33 52-week low $12.13
Day low $15.02 Volume 47,874
Day high $15.49 Avg. volume 605,676
50-day MA $16.41 Dividend yield N/A
200-day MA $16.48 Market Cap 530.49M

Zynex Inc. (ZYXI) Company Bio


Zynex Inc., through its subsidiary, markets electro therapy products which help improve life of patients who have functional disabilities. The Company's products include muscle stimulation, inferential, and TENS devices. Zynex products are intended for home use for stroke rehabilitation, spinal cord injury rehabilitation, incontinence, and other applications.


ZYXI Latest News Stream


Event/Time News Detail
Loading, please wait...

ZYXI Latest Social Stream


Loading social stream, please wait...

View Full ZYXI Social Stream

Latest ZYXI News From Around the Web

Below are the latest news stories about Zynex Inc that investors may wish to consider to help them evaluate ZYXI as an investment opportunity.

Zynex 1Q21 orders grow 140% Y/Y, sees revenues estimates in-line

Zynex ([[ZYXI]] -3.5%) announces Q1 order growth of 140% Y/Y, and confirms its previous revenue estimate 1Q21 of between $23M and $24.5M vs. consensus of $23.8M and Adj. EBITDA loss estimate of between $0.5M and $1.5M.FY21 revenue estimate is between $135M and $150M vs. consensus of $138.03M; and Adj. EBITDA...

Seeking Alpha | April 12, 2021

Zynex Growth Leads to New Corporate Headquarters

Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced that it is moving to a new corporate headquarters to accommodate its' continued growth. The new headquarters is located at 9655 Maroon Circle, Englewood CO 80112.

Yahoo | April 9, 2021

Could The Market Be Wrong About Zynex, Inc. (NASDAQ:ZYXI) Given Its Attractive Financial Prospects?

With its stock down 9.0% over the past month, it is easy to disregard Zynex (NASDAQ:ZYXI). But if you pay close...

Yahoo | April 8, 2021

Zynex Recognized as the Sixth Largest Biotechnology/Bioscience Company in Colorado

Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics today announced the Denver Business Journal has recognized Zynex as the sixth largest Biotechnology/Bioscience public company in Colorado based on number of companywide employees as of November 1, 2020.

Yahoo | March 30, 2021

Zynex Plans To Buy Back $10M In Stock; Shares Jump Over 10%

Shares of Zynex closed 10.1% higher on Monday after the medical device manufacturer announced its plans to repurchase $10 million worth of shares. Zynex (ZYXI) said that the repurchase program will commence immediately and is set to expire on Sep. 8, or before the buyback limit of $10 million is reached. The company’s CEO Thomas Sandgaard said, “this buyback program authorization reflects the board's confidence in both our short-term prospects and our long term growth strategy.” He added that, “the buyback program represents an attractive opportunity to deploy capital in a way that will benefit stockholders.” Last month, Zynex reported lower-than-expected 4Q results. The company reported 4Q earnings of $0.

Amit Singh on TipRanks | March 9, 2021

Read More 'ZYXI' Stories Here

ZYXI Price Returns

1-mo -6.63%
3-mo -7.87%
6-mo 8.25%
1-year 22.94%
3-year 341.16%
5-year N/A
YTD 13.08%
2020 71.03%
2019 167.69%
2018 -7.55%
2017 960.00%
2016 -33.77%

Continue Researching ZYXI

Here are a few links from around the web to help you further your research on Zynex Inc's stock as an investment opportunity:

Zynex Inc (ZYXI) Stock Price | Nasdaq
Zynex Inc (ZYXI) Stock Quote, History and News - Yahoo Finance
Zynex Inc (ZYXI) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 1.1711 seconds.